Hepatitis C Treatment in Idaho County Jails

Sponsor
Eastern Idaho Public Health
Study ID
NCT06533319
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • sofosbuvir/velpatasvir — DRUG
    Patients who qualify for the study will be provided with sofosbuvir/velpatasvir for chronic hepatitis C treatment.

Study Details

To explore the feasibility of opt in Hepatitis C Virus (HCV) screening and initiation of HCV treatment during incarceration in county jails including; 1. incarcerated persons positive for HCV who remain in jail for duration of 12 weeks of treatment and 2. incarcerated persons positive for HCV in jails less than the duration of 12 weeks of treatment who receive remaining supply of study drug on discharge with appropriate linkage to care. Assess quality of life measures in participants being treated for their HCV through the validated questionnaire EuroQol-5D at baseline and post-treatment.

Key Dates

First listed
Aug 1, 2024
Start date
Aug 1, 2024
Status verified
Jul 2024
Primary completion
Feb 1, 2025
Completion
Aug 1, 2025

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Patients infected with chronic hepatitis C who are also incarcerated in an Idaho county jail
    Patients infected with chronic hepatitis C who are also incarcerated will be enrolled into the study and provided FDA approved Epclusa (sofosbuvir/velpatasvir) for treatment of chronic hepatitis C. Epclusa (sofosbuvir/velpatasvir) is currently used as a first line treatment for chronic hepatitis C. This study will focus on effectiveness of treatment in the county jai setting.

Primary Outcome Measure

Sustained Virologic Response [ Time Frame: 12 weeks after treatment ]

Related Studies